• Explore /
  • Poster
  • / Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.

Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.

Abstract Video & Slides Poster

Authors

null

Seiichi Hayato

Eisai Co. Ltd., Tokyo, Japan

Seiichi Hayato , Lora Hamuro , Maiko Nomoto , Shin Nishio , Kan Yonemori , Mayu Yunokawa , Koji Matsumoto , Kazuhiro Takehara , Kosei Hasegawa , Yasuyuki Hirashima , Hidenori Kato , Toshio Shimizu , Hiroki Ikezawa , Yohei Otake , Takuma Miura , Yue Zhao , Li Zhu , Trixia Camacho , Calin Dan Dumitru , Sanae Yasuda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Pharmacology/Pharmacodynamics/Pharmacogenetics

Clinical Trial Registration Number

NCT03386942

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3090)

DOI

10.1200/JCO.2022.40.16_suppl.3090

Abstract #

3090

Poster Bd #

82

Abstract Disclosures

Similar Posters

First Author: David S. Hong

First Author: Doris M. Ponce

First Author: Krish Patel

First Author: Sikander Ailawadhi